Active substance |
Esketamine |
Holder |
Janssen-Cilag |
Status |
Running |
Indication |
ESK is intended for treatment‐resistant depression (Major Depressive Disorder in adults who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode). ESK must be given in combination with an SSRI or SNRI. |
Public documents |
|
Last update |
21/09/2020 |
Esketamine
Last updated on 13/02/2024